文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

孕妇疟疾疫苗试验:尚无先例的迫切需求

Malaria vaccine trials in pregnant women: An imperative without precedent.
PubMed 文献 · Vaccine · 2019-01-06

孕妇对恶性疟原虫疟疾高度易感,导致大量孕产妇、围产期和婴儿死亡,但从未在孕妇中开展过疟疾疫苗试验。专家起草了孕期测试疟疾疫苗的临床开发计划,以Sanaria公司正在2期测试的PfSPZ疫苗为案例,并在马里Ouelessebougou启动妊娠登记以提供母婴结局基线信息。

要点

  • 孕妇对恶性疟原虫疟疾高度易感,但疟疾疫苗从未在孕妇中试验。
  • 专家会议支持在孕妇中测试直接受益的疟疾疫苗,需符合国际安全标准。
  • 初步安全性和免疫原性研究在非孕成人中进行,疗效试验在疟疾流行区孕妇中开展。

核心结论

  • 孕妇疟疾疫苗试验虽无先例但迫在眉睫,专家支持在确保母婴安全前提下推进临床开发。

主要发现

  • 孕妇对恶性疟原虫疟疾高度易感,导致大量孕产妇、围产期和婴儿死亡。
  • 疟疾疫苗开发近年取得显著进展,但从未在孕妇中开展试验。
  • 孕产妇免疫领域进展及监管伦理环境演变支持测试直接惠及孕妇的疟疾疫苗。

关键数值与推荐

  • 初步安全性和免疫原性研究在非孕成人志愿者中进行。
  • 疗效试验可能在疟疾流行且资源匮乏环境中开展,需足够高疟疾发病率以测量疫苗活性。
  • 试验需符合所有国际标准,确保母婴安全,并接受适当伦理和监管机构监督。

临床怎么用

  • 在马里Ouelessebougou启动妊娠登记,提供母婴结局基线信息以评估未来PfSPZ疫苗安全性。
  • 正在评估适合孕妇评价的新方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnant women are highly susceptible to Plasmodium falciparum malaria, leading to substantial maternal, perinatal, and infant mortality. While malaria vaccine development has made significant progress in recent years, no trials of malaria vaccines have ever been conducted in pregnant women. In December 2016, an expert meeting was convened at NIAID, NIH, in Rockville, Maryland to deliberate on the rationale and design of malaria vaccine trials in pregnant women. The discussions highlighted the progress made over recent years in the field of maternal immunization for other infectious diseases, and the evolving regulatory and ethical environment, all of which support a new emphasis on testing malaria vaccines that offer direct benefits to pregnant women. Initial safety and immunogenicity studies of malaria vaccines will be conducted in non-pregnant adult volunteers. Subsequently, efficacy trials involving pregnant women will likely be conducted in malaria-endemic and often resource-poor environments where sufficiently high malaria incidence will allow vaccine activity to be measured. Such trials will need to meet all international standards to ensure the safety of mother and offspring, under oversight of appropriate ethical and regulatory bodies. The convened experts drafted a clinical development plan to test a malaria vaccine product during pregnancy, using as a case study PfSPZ Vaccine being developed by Sanaria Inc. that is currently in phase 2 testing. Following the expert recommendations, a pregnancy registry has been initiated in Ouelessebougou, Mali, to provide baseline information on maternal and fetal outcomes as a context for evaluating PfSPZ Vaccine safety in the future, and new regimens are being assessed that will be suitable for evaluation in pregnant women.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Healy SA, Fried M, Richie T, et al. Malaria vaccine trials in pregnant women: An imperative without precedent. Vaccine. 2019. PMID: 30621913. doi:10.1016/j.vaccine.2018.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。